In patients with metastatic breast cancer (mBC) who progress after first-line treatment of CDK4/6 and aromatase inhibitors ...
The Chosun Ilbo on MSN
Antibody-drug conjugates transform metastatic breast cancer care
Breast cancer has a survival rate of over 95% when detected early, but this drops sharply to around 40% in cases of ...
The landscape of triple-negative breast cancer (TNBC) is shifting rapidly. What was once a landscape dominated by standard cytotoxic chemotherapy is now a complex map of immunotherapy, PARP inhibitors ...
AstraZeneca & Daiichi Sankyo’s Datroway granted Priority Review in US as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy: Cambridge ...
February 2026.) AstraZeneca full-year earnings: can the pharma giant maintain oncology momentum? AstraZeneca is set to release its full-year 2025 (FY25) financial results on 10 February 2026, a mil ...
Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results